J J Vehreschild1, A Böhme2, O A Cornely3, C Kahl4, M Karthaus5, K-A Kreuzer1, G Maschmeyer6, S Mousset7, V Ossendorf8, O Penack9, M J G T Vehreschild1, J Bohlius10. 1. 1st Department of Internal Medicine, University Hospital of Cologne, Cologne. 2. Onkologikum Frankfurt am Museumsufer, Frankfurt a.M. 3. 1st Department of Internal Medicine, University Hospital of Cologne, Cologne Clinical Trials Centre Cologne (ZKS Köln, BMBF 01KN1106) Centre for Integrated Oncology CIO KölnBonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne oliver.cornely@uk-koeln.de. 4. Clinic for Haematology and Oncology, Klinikum Magdeburg gGmbH, Magdeburg. 5. Haematology-Oncology and Palliative Care, Hospital Neuperlach and Hospital Harlaching, Munich. 6. Department of Haematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam. 7. Medizinische Klinik II, University Hospital Frankfurt a.M., Frankfurt a.M. 8. Clinical Trials Centre Cologne (ZKS Köln, BMBF 01KN1106). 9. Campus Benjamin Franklin; Medical Clinic for Haematology and Oncology, University Hospital Charité, Berlin, Germany. 10. Institute for Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Abstract
BACKGROUND: Current evidence on myelopoietic growth factors is difficult to overview for the practicing haematologist/oncologist. International guidelines are sometimes conflicting, exclude certain patient groups, or cannot directly be applied to the German health system. This guideline by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO) gives evidence-based recommendations for the use of G-CSF, pegylated G-CSF, and biosimilars to prevent infectious complications in cancer patients undergoing chemotherapy, including those with haematological malignancies. METHODS: We systematically searched and evaluated current evidence. An expert panel discussed the results and recommendations. We then compared our recommendations to current international guidelines. RESULTS: We summarised the data from eligible studies in evidence tables, developed recommendations for different entities and risk groups. CONCLUSION: Comprehensive literature search and expert panel consensus confirmed many key recommendations given by international guidelines. Evidence for growth factors during acute myeloid leukaemia induction chemotherapy and pegfilgrastim use in haematological malignancies was rated lower compared with other guidelines.
BACKGROUND: Current evidence on myelopoietic growth factors is difficult to overview for the practicing haematologist/oncologist. International guidelines are sometimes conflicting, exclude certain patient groups, or cannot directly be applied to the German health system. This guideline by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO) gives evidence-based recommendations for the use of G-CSF, pegylated G-CSF, and biosimilars to prevent infectious complications in cancerpatients undergoing chemotherapy, including those with haematological malignancies. METHODS: We systematically searched and evaluated current evidence. An expert panel discussed the results and recommendations. We then compared our recommendations to current international guidelines. RESULTS: We summarised the data from eligible studies in evidence tables, developed recommendations for different entities and risk groups. CONCLUSION: Comprehensive literature search and expert panel consensus confirmed many key recommendations given by international guidelines. Evidence for growth factors during acute myeloid leukaemia induction chemotherapy and pegfilgrastim use in haematological malignancies was rated lower compared with other guidelines.
Authors: Nicole Skoetz; Julia Bohlius; Andreas Engert; Ina Monsef; Oliver Blank; Jörg-Janne Vehreschild Journal: Cochrane Database Syst Rev Date: 2015-12-21
Authors: M G Kiehl; G Beutel; B Böll; D Buchheidt; R Forkert; V Fuhrmann; P Knöbl; M Kochanek; F Kroschinsky; P La Rosée; T Liebregts; C Lück; U Olgemoeller; E Schalk; A Shimabukuro-Vornhagen; W R Sperr; T Staudinger; M von Bergwelt Baildon; P Wohlfarth; V Zeremski; P Schellongowski Journal: Ann Hematol Date: 2018-04-27 Impact factor: 3.673
Authors: Marie von Lilienfeld-Toal; Jörg Janne Vehreschild; Oliver Cornely; Livio Pagano; Francesca Compagno; Hans H Hirsch Journal: Leukemia Date: 2020-05-01 Impact factor: 11.528
Authors: Nicola Giesen; Rosanne Sprute; Maria Rüthrich; Yascha Khodamoradi; Sibylle C Mellinghoff; Gernot Beutel; Catherina Lueck; Michael Koldehoff; Marcus Hentrich; Michael Sandherr; Michael von Bergwelt-Baildon; Hans-Heinrich Wolf; Hans H Hirsch; Bernhard Wörmann; Oliver A Cornely; Philipp Köhler; Enrico Schalk; Marie von Lilienfeld-Toal Journal: Eur J Cancer Date: 2020-09-21 Impact factor: 9.162
Authors: Annika Y Classen; Larissa Henze; Marie von Lilienfeld-Toal; Georg Maschmeyer; Michael Sandherr; Luisa Durán Graeff; Nael Alakel; Maximilian Christopeit; Stefan W Krause; Karin Mayer; Silke Neumann; Oliver A Cornely; Olaf Penack; Florian Weißinger; Hans-Heinrich Wolf; Jörg Janne Vehreschild Journal: Ann Hematol Date: 2021-04-13 Impact factor: 3.673
Authors: Annika Yanina Classen; Michael Sandherr; Jörg Janne Vehreschild; Marie von Lilienfeld-Toal Journal: Onkologe (Berl) Date: 2022-03-15 Impact factor: 0.170